CIBC Asset Management Inc Acquires 1,868 Shares of Eli Lilly and Company (LLY)

CIBC Asset Management Inc raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,720 shares of the company’s stock after acquiring an additional 1,868 shares during the quarter. CIBC Asset Management Inc’s holdings in Eli Lilly and were worth $9,043,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of LLY. Advantus Capital Management Inc increased its holdings in Eli Lilly and by 0.4% during the 1st quarter. Advantus Capital Management Inc now owns 97,698 shares of the company’s stock valued at $8,217,000 after acquiring an additional 425 shares in the last quarter. Modera Wealth Management LLC acquired a new stake in shares of Eli Lilly and during the 1st quarter worth about $238,000. Partnervest Advisory Services LLC boosted its stake in shares of Eli Lilly and by 12.4% during the 1st quarter. Partnervest Advisory Services LLC now owns 5,820 shares of the company’s stock worth $489,000 after purchasing an additional 643 shares during the last quarter. Stephens Inc. AR boosted its stake in shares of Eli Lilly and by 4.5% during the 1st quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock worth $3,703,000 after purchasing an additional 1,901 shares during the last quarter. Finally, Bellevue Group AG boosted its stake in shares of Eli Lilly and by 275.4% during the 1st quarter. Bellevue Group AG now owns 131,400 shares of the company’s stock worth $11,052,000 after purchasing an additional 96,400 shares during the last quarter. Hedge funds and other institutional investors own 76.42% of the company’s stock.

Shares of Eli Lilly and Company (NYSE LLY) opened at $86.54 on Friday. The stock has a market cap of $95,321.79, a P/E ratio of 21.17, a PEG ratio of 1.76 and a beta of 0.35. Eli Lilly and Company has a 12 month low of $71.76 and a 12 month high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The business’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.88 earnings per share. sell-side analysts forecast that Eli Lilly and Company will post 4.22 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.60%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.

Several equities research analysts have issued reports on the stock. Credit Suisse Group reaffirmed a “hold” rating on shares of Eli Lilly and in a research note on Wednesday. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, December 12th. Morgan Stanley raised their target price on shares of Eli Lilly and from $86.00 to $90.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 21st. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Berenberg Bank reissued a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a research report on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $90.25.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the sale, the senior vice president now owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Insiders have sold 651,088 shares of company stock worth $56,439,586 in the last quarter. Insiders own 0.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “CIBC Asset Management Inc Acquires 1,868 Shares of Eli Lilly and Company (LLY)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/12/17/cibc-asset-management-inc-acquires-1868-shares-of-eli-lilly-and-company-lly.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply